NasdaqGM:NRIXBiotechs
Does New NX-5948 Phase 2 Dose Selection Change The Bull Case For Nurix Therapeutics (NRIX)?
Nurix Therapeutics, Inc. recently presented new clinical data from its ongoing Phase 1a/1b NX-5948-301 trial of bexobrutideg (NX-5948) in relapsed or refractory B-cell malignancies at the 67th American Society of Hematology Annual Meeting, including safety and efficacy findings across multiple dose levels and patient cohorts.
The data underpin selection of a 600 mg dose as the recommended Phase 2 level and support Nurix’s pivotal DAYBreak development program under FDA initiatives Project...